PPBT PPBT
Company Profile ↓Company Overview
PPBT (PPBT) is a publicly traded company listed on with a market capitalization of $2.79B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -93.21% |
| 6 Months: | -74.53% |
| 3 Months: | -64.45% |
| 1 Month: | -5.66% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.06 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 93.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 1.41M | 1.24M | 1.37M | 2.96M | 2.25M |
| Operating Income | - | -1.41M | -1.24M | -1.37M | -2.96M | -2.25M |
| EBITDA | - | -376.00K | -1.04M | -1.24M | -23.57M | 7.00K |
| Interest Expense | - | 35.00K | 0 | 5.00K | 23.00K | 31.00K |
| Pretax Income | - | -456.00K | -1.09M | -1.30M | -23.64M | -89.00K |
| Tax Provision | - | - | - | - | - | - |
| Net Income | - | -453.00K | -1.08M | -1.30M | -23.55M | -86.00K |
| Diluted EPS | - | -3,460.00 | -4.00 | -2.00 | -200.00 | -180.00 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 22.60M | 22.27M | 10.80M | 6.98M |
| Operating Income | - | -22.60M | -22.27M | -10.80M | -6.98M |
| EBITDA | - | -21.49M | -19.72M | -7.05M | -26.25M |
| Interest Expense | - | 67.00K | 56.00K | 41.00K | 39.00K |
| Pretax Income | - | -21.76M | -19.98M | -7.28M | -26.49M |
| Tax Provision | 0 | - | - | - | - |
| Net Income | - | -21.67M | -19.88M | -7.24M | -26.39M |
| Diluted EPS | - | -240.00 | -178.00 | -44.16 | -54.00 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 54.62M | 44.30M | 37.04M | 17.57M |
| Current Assets | - | 33.26M | 15.79M | 8.91M | 9.87M |
| Cash & Equivalents | - | 15.03M | 14.49M | 7.40M | 8.72M |
| Inventory | - | - | - | - | - |
| Receivables | - | 997.00K | 205.00K | 275.00K | 155.00K |
| Total Liabilities | - | 7.52M | 10.01M | 4.13M | 7.91M |
| Current Liabilities | - | 7.06M | 9.70M | 3.99M | 7.75M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 515.00K | 351.00K | 183.00K | 244.00K |
| Total Equity | - | 46.91M | 34.21M | 32.86M | 9.71M |
| Shares Outstanding | - | 184.82M | 252.38M | 517.13M | 1.86B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -16.73M | -19.93M | -14.37M | -5.66M |
| Investing Cash Flow | - | 19.91M | 13.88M | 509.00K | 632.00K |
| Financing Cash Flow | - | 1.11M | 5.45M | 6.77M | 6.33M |
| Capital Expenditure | -115.00K | -228.00K | -3.00K | - | -3.00K |
| Free Cash Flow | - | -16.96M | -19.93M | -14.37M | -5.66M |
| Net Change in Cash | - | 4.29M | -595.00K | -7.08M | 1.31M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -46.2% | -58.1% | -22.0% | -271.6% |
| ROCE % | - | -47.5% | -64.4% | -32.7% | -71.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PPBT
PURPLE BIOTECH LTD-ADR (PPBT) Stock Price & Overview - ChartMill
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBrQ3RETjN3NlNSbU5Ybmw0OEhJc1VfbkFVTks0TWVFNEpNcmwxZXBOZXZhcFNDZVdfMFRtdjlKN2Y4bm15SmhQVGdubUs3OUZPV0xicks2UFA3eS1saFJj?oc=5" target="_blank">PURPLE BIOTECH LTD-ADR (PPBT) Stock Pri…
Purple Biotech Ltd. Revenue Breakdown – TASE:PPBT - TradingView
<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE9xaHg5bmFYSnJIUUMyVzNqVFFhbHdtMDBodmhBbFdTQi1weHRmTFZmZGFCdVJnZjhGMTRRUU5FS1RORFBDZjVBWkRkaFBPV054Rkh3Znh3VWlPMUFIV3ZxYm1UTWJlQ0R2QlRVWURTUmVudmFL?oc=5" target="_blank">Purple Biot…
PPBT Stock Slides As Traders Weigh Deep Value Signals - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFAxS3BiQXRTWF9RNTlkT1ZzTC1aYnR6VExaTkMtVDgyUzRCTWRLR1ZfeUFRclBLeS1Wb2o1ZGl6MWRMSkpWdzRyTEExRWpBemlwRkhjUXRWN1NieU45ODFwamE5dXFsY0h1ZXhvcmxrLTBEaVdTNkROa19B?oc=5" target="_blank">PPB…
PPBT Stock Slides As Traders Watch Key Support Levels - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMie0FVX3lxTE1RY1ZkSjA3b0x1Z05vUFk1QjhJd3RMRDVKMklzdzJiMjM3Y3VsQ0g1OXM4RGVTWWRzd2t6NWs5dDlXb3dFNUZJWGpwaHJHYUtLZF9rZzIzSFpsOWU0RkZyZkxTUU9HTTI0ZVV5bkJ0cjYxRThVbzR2YU15Zw?oc=5" target="_blank">P…
Purple Biotech (NASDAQ: PPBT) posts promising IM1240 preclinical data at EACR 2026 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPQ1VLblBNN0t1TndwUjU5cHYxc1VFZDNnLTF4UmNoNXdIWmdFNFkycnF4OWpBNnRyUVZ6VXJtVFVTMTI1aS0xbVEzSXFicDNzVVlHVWdIYndrdWFJWjRuX28tSHBhOEhHVjh5MHl1VjY0dnlIRjlqUm05bmdFZ2JJbndxd1Fnc1NYZGVUNk…
Purple Biotech Announces Plan to Implement ADS Ratio Change - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPY0hicGpJb1Y4VkVlSG9JemNSSmh6T2JXNGR6R0lqQ3VSVFA0bUpHc0dtdWR4Qmh1TEk0WnE4RGZLTXhGLVBoMC1HTEdfcUVyRlhwcDRfY3JjcTctdHhiWnhnWW5KUV9uYXNERGhROHlvYXFscXlWM0ttOG1Na0l3NWxoYm9rZVhvX3EtZF…
PPBT — Frequently Asked Questions
What is the current share price of PPBT?
As of 2026-08-05 17:25 PDT, PPBT trades at $1.50 on NASDAQ/NYSE. Its 52-week range is $1.33 to $23.10.
What is the market capitalisation of PPBT?
PPBT has a market capitalisation of $2.79B on NASDAQ/NYSE.
What is the P/E ratio of PPBT?
PPBT trades at a trailing price-to-earnings (P/E) ratio of -0.03. Its price-to-book (P/B) ratio is 288.46.
Is PPBT a good stock to buy?
This page provides a data-driven analysis of PPBT, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.